Claims for Patent: 8,871,449

Summary for Patent: 8,871,449

Title:	Methods and products for evaluating an immune response to a therapeutic protein
Abstract:	The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
Inventor(s):	Subramanyam; Meena (Stoneham, MA), Amaravadi; Lakshmi (Natick, MA), Wakshull; Eric (Princeton, MA), Lynn; Frances (Somerville, MA), Panzara; Michael (Winchester, MA), Barbour; Robin McDaid (Walnut Creek, CA), Taylor; Julie Elizabeth (San Francisco, CA)
Assignee:	Biogen Idec MA Inc. (Cambridge, MA)
Application Number:	13/242,505
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,871,449
Patent Claims:	1. A method of monitoring an immune response to natalizumab in a subject treated with natalizumab, the method comprising: performing an antibody detection assay on a biological sample taken from a subject treated with natalizumab to determine whether the biological sample contains at least a threshold level of anti-natalizumab antibody binding activity, wherein the threshold level is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 200 ng/ml of anti-natalizumab antibody, and wherein the presence of at least the threshold level of anti-natalizumab antibody binding activity in the biological sample indicates a reduction in, or absence of, therapeutic efficacy of natalizumab. 2. The method of claim 1, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising at least 300 ng/ml of anti-natalizumab antibody. 3. The method of claim 2, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising at least 400 ng/ml of anti-natalizumab antibody. 4. The method of claim 3, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody. 5. The method of claim 4, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising at least 600 ng/ml of anti-natalizumab antibody. 6. The method of claim 5, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising at least 800 ng/ml of anti-natalizumab antibody. 7. The method of claim 6, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising at least 1000 ng/ml of anti-natalizumab antibody. 8. The method of claim 1, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising between 400 and 600 ng/ml of anti-natalizumab antibody. 9. The method of claim 8, wherein the threshold level is equal to the level of binding activity present in a reference sample comprising between 450 and 550 ng/ml of anti-natalizumab antibody. 10. The method of claim 1, where the antibody detection assay is performed in two or more biological samples taken from the subject at different time points. 11. The method of claim 1, where the antibody detection assay is performed in two biological samples taken from the subject at different time points separated by at least one month. 12. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity is measured in a first aliquot of the biological sample, and wherein the method further comprises determining the binding specificity of the anti-natalizumab antibody for natalizumab. 13. The method of claim 12, wherein the binding specificity of the anti-natalizumab antibody is determined in a second aliquot of the biological sample. 14. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity is determined by comparing levels of binding to a labeled VLA-4 binding antibody measured in the presence of two or more different amounts of unlabeled VLA-4 binding antibody. 15. The method of claim 1, wherein the level of anti-natalizumab antibody is determined by comparing levels of binding to an immobilized VLA-4 binding antibody measured in the presence of two or more different amounts of soluble VLA-4 binding antibody. 16. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity is determined by comparing a first level of binding to a labeled VLA-4 binding antibody measured in the presence of a first amount of unlabeled VLA-4 binding antibody to a second level of binding to a labeled VLA-4 binding antibody measured in the presence of a second amount of unlabeled VLA-4 binding antibody. 17. The method of claim 1, wherein a bridging ELISA assay is performed to determine whether the biological sample contains the threshold level of anti-natalizumab antibody binding activity. 18. The method of claim 1, wherein the subject is a human subject. 19. The method of claim 1, wherein the subject has multiple sclerosis, rheumatoid arthritis, or Crohn's disease. 20. The method of claim 1, wherein biological sample is a serum sample. 21. The method of claim 1, further comprising selecting a therapeutic regimen for the subject if a threshold level of anti-natalizumab antibody binding activity is determined to be present in the biological sample from the subject. 22. The method of claim 21, wherein selecting a therapeutic regimen comprises, evaluating a current therapy of the subject, determining a new therapy for the subject, modifying a current therapy of the subject, or stopping a current therapy of the subject. 23. The method of claim 22, wherein a current therapy comprises administering natalizumab to the subject. 24. The method of claim 1, further comprising continuing a therapeutic regimen for the subject if a threshold level of anti-natalizumab antibody binding activity is determined not to be present in the biological sample from the subject. 25. The method of claim 24, wherein the therapeutic regimen comprises administering natalizumab to the subject. 26. A method of monitoring an immune response to natalizumab in a subject treated with natalizumab, the method comprising: performing an antibody detection assay on a biological sample taken from a subject treated with natalizumab to determine whether the biological sample contains at least a threshold level of anti-natalizumab antibody, wherein the threshold level is 500 ng/ml, and wherein the presence of at least the threshold level of anti-natalizumab antibody in the biological sample indicates a reduction in, or absence of, therapeutic efficacy of natalizumab. 27. The method of claim 26, where the antibody detection assay is performed in two or more biological samples taken from the subject at different time points. 28. The method of claim 26, where the antibody detection assay is performed in two biological samples taken from the subject at different time points separated by at least one month.

Details for Patent 8,871,449

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2025-04-04